Zevra Therapeutics (ZVRA) +21.3% — Celiprolol Wins Key FDA Designations
‍

Zevra Therapeutics jumped 21.3% in one day after announcing that Celiprolol received both Orphan Drug and Breakthrough Therapy designations from the U.S. FDA.
‍

The designations are important because they can help speed development and review while also strengthening the commercial outlook if the drug is approved. Investors reacted positively because the update signals growing regulatory support for Celiprolol and improves the odds that the program could move forward more quickly.

‍

Karat Packaging (KRT) +21% — Strong Earnings + Buyback
‍

Karat Packaging rose 21% after reporting strong Q4 and full-year 2025 results, including record fourth-quarter sales of $115.6 million, up 13.7% year over year, while net income climbed 22.8% to $7.2 million.
‍

The report also showed that the company is still growing profitably despite tariff pressure, with management guiding for continued sales growth and improving margins in 2026. Investors were further encouraged by the company’s shareholder return story, as Karat disclosed that $12.0 million remains available under its share repurchase program, signaling flexibility to keep buying back stock while the business expands.